Trial Landscape News Today

I almost wanted to encourage him to take a few minutes out of 9 00 to tell the people. Preached the gospel. Its good stuff. Theres a lot in there. Its wild. It really is. Its true and sort of were programmatic policies and people sense of who actually gets them or who was on their side and how they interact. Is pretty interesting. Its like in hindsight obamas total acquiescence to the Label Obamacare seems quite wise as a political strategy. All right, my friend, have a good weekend. You are don...

While that case moves forward, the others not so much. The federal elections case brought by special counsel jack smith suffered a huge setback this week when the Supreme Court stepped in and delayed the start date of that trial. Potentially pushing it back until after the november election, which leads to other trials. Today we got significant updates on both of those cases. Today in florida, for the first time ever, both donald trump and jack smith were in public court together. For the case o...

Pro version of H1’s proprietary GenAI tool expands access to insights within the Trial Landscape solution to facilitate clinical trial design

In recent years, the financial sector has seen some of the biggest changes in the way technology is used. New regulations and disruptive technologies like blockchain, along with the rise of open banking, have seen traditional players scrambling to keep up with more agile newcomers.

A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.

H1, the leading source of truth for global Healthcare Professional, clinical, scientific, and research information, today announced the launch of GenosAI, a new generative AI tool seamlessly embedded into its clinical trial intelligence platform, Trial Landscape, to analyze and respond to all types of complex inquiries.

H1, the leading source of truth for global Healthcare Professional, clinical, scientific, and research information, today announced the

Too often, there is an underrepresentation of one key group or another in clinical trial subject populations.

H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.

H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.